<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520789</url>
  </required_header>
  <id_info>
    <org_study_id>09.01.10002</org_study_id>
    <nct_id>NCT04520789</nct_id>
  </id_info>
  <brief_title>Early Prevention Strategies of Severe Proliferative Vitreoretinopathy Base on Precision Diagnosis of Single Cell Sequencingvitreoretinopathy</brief_title>
  <official_title>Early Prevention Strategies of Severe Proliferative Vitreoretinopathy Base on Precision Diagnosis of Single Cell Sequencing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells&#xD;
      (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients; to prove the&#xD;
      percentage of PVR-IC decides the risk of serious PVR occurring after surgery; to investigate&#xD;
      the safety and efficacy of early local steroids drug intervention in patients with severe&#xD;
      postoperative PVR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retina reattachment rate</measure>
    <time_frame>3 months post operation</time_frame>
    <description>Percentage of participants whose fundus achieved the following conditions simultaneously (B-mode ultrasound showed retinal detachment band height was 0mm, OCT showed subretinal fluid height was 0um)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Severe PVR</measure>
    <time_frame>3 months post operation</time_frame>
    <description>Number of participants whose fundus achieved the following conditions simultaneously (B-mode ultrasound showed proliferative band height exceeded 0mm, OCT showed proliferative band exceeded 0um)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best Corrected visual Acuity (BCVA）</measure>
    <time_frame>3 months post operation</time_frame>
    <description>Patients' best corrected visual acuity assessed by logarithmic visual acuity(0.5-1.0； For example, normal vision was 1.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure (IOP)</measure>
    <time_frame>3 months post operation</time_frame>
    <description>Patients' IOP(mmHg) assessed by noncontact tonometer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retina reattachment rate</measure>
    <time_frame>12 months post operation</time_frame>
    <description>Percentage of participants whose fundus achieved the following conditions simultaneously (B-mode ultrasound showed retinal detachment band height was 0mm, OCT showed subretinal fluid height was 0um)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Severe PVR</measure>
    <time_frame>12 months post operation</time_frame>
    <description>Number of participants whose fundus achieved the following conditions simultaneously (B-mode ultrasound showed proliferative band height exceeded 0mm, OCT showed proliferative band exceeded 0um)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected visual Acuity (BCVA）</measure>
    <time_frame>12 months post operation</time_frame>
    <description>Patients' best corrected visual acuity assessed by logarithmic visual acuity(0.5-1.0； For example, normal vision was 1.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure (IOP)</measure>
    <time_frame>12 months post operation</time_frame>
    <description>Patients' IOP(mmHg) assessed by noncontact tonometer</description>
  </secondary_outcome>
  <other_outcome>
    <measure>RD treatment group1and RD treatment group2</measure>
    <time_frame>1 weeks post operation,3 months post operation,12 months post operation</time_frame>
    <description>Proportion (%)of PVR-IC subtypes in RPE cells assessed by 10×Genomics single cell sequencing</description>
  </other_outcome>
  <other_outcome>
    <measure>RD treatment group2</measure>
    <time_frame>2 weeks post operation,3 months post operation,12 months post operation</time_frame>
    <description>Patients' IOP (mmHg)assessed by noncontact tonometer; len's opacity(Grade1-4) assessed by PENTACAM; number of participants who occurred subconjunctival chemosis and hemorrhage(area 1/4-1)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rhegmatogenous Retinal Detachment</condition>
  <arm_group>
    <arm_group_label>RD control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Conventional Surgery for Retinal Detachment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RD treatment group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional Surgery for Retinal Detachment，RPE cell collection, single cell heterogeneity study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RD treatment group2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional Surgery for Retinal Detachment，RPE cell collection, single cell heterogeneity study, postoperative intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>RPE cell collection and single cell heterogeneity study</intervention_name>
    <description>Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients, the percentage of which decides the risk of serious PVR occurring after surgery.</description>
    <arm_group_label>RD treatment group1</arm_group_label>
    <arm_group_label>RD treatment group2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Postoperative intervention</intervention_name>
    <description>Early local steroids drug intervention in patients with severe postoperative PVR</description>
    <arm_group_label>RD treatment group2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Surgery for Retinal Detachment</intervention_name>
    <description>Conventional Surgery for Retinal Detachment</description>
    <arm_group_label>RD control group</arm_group_label>
    <arm_group_label>RD treatment group1</arm_group_label>
    <arm_group_label>RD treatment group2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) Age: 18-60 years old, regardless of gender; (2) Clinical diagnosis of with&#xD;
             rhegmatogenic retinal detachment (RRD); (3) Surgery for Retinal Detachment is&#xD;
             required; (4) Myopia &lt; = 800 degrees; (4) PVR classification: no restrictions; (5)&#xD;
             Patients undergoing the first or second operation. (6) Patients volunteered to&#xD;
             participate in this study and signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) Exudative detachment of retina; (2) Those who are allergic to the drugs used in&#xD;
             the study; (3) Combined with other eye diseases: other fundus diseases, glaucoma,&#xD;
             corneal opacity diseases, genetic diseases); (4) history of internal eye surgery &gt;=3&#xD;
             times; (5) Postoperative follow-up could not be scheduled; (6) Patients with systemic&#xD;
             diseases (such as asthma, heart failure, myocardial infarction, liver failure, kidney&#xD;
             failure and other major diseases).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fang Wang, MD,phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of ophthalmology, Shanghai Tenth People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fang Wang, MD,phD</last_name>
    <phone>+86-18917683335</phone>
    <email>18917683335@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Conghui Zhang, MD,phD</last_name>
    <phone>+86-13671886466</phone>
    <email>linghui0224@126.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Moncada R, Barkley D, Wagner F, Chiodin M, Devlin JC, Baron M, Hajdu CH, Simeone DM, Yanai I. Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas. Nat Biotechnol. 2020 Mar;38(3):333-342. doi: 10.1038/s41587-019-0392-8. Epub 2020 Jan 13. Erratum in: Nat Biotechnol. 2020 Dec;38(12):1476.</citation>
    <PMID>31932730</PMID>
  </reference>
  <reference>
    <citation>Voigt AP, Mulfaul K, Mullin NK, Flamme-Wiese MJ, Giacalone JC, Stone EM, Tucker BA, Scheetz TE, Mullins RF. Single-cell transcriptomics of the human retinal pigment epithelium and choroid in health and macular degeneration. Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24100-24107. doi: 10.1073/pnas.1914143116. Epub 2019 Nov 11.</citation>
    <PMID>31712411</PMID>
  </reference>
  <reference>
    <citation>Hu Y, Wang X, Hu B, Mao Y, Chen Y, Yan L, Yong J, Dong J, Wei Y, Wang W, Wen L, Qiao J, Tang F. Dissecting the transcriptome landscape of the human fetal neural retina and retinal pigment epithelium by single-cell RNA-seq analysis. PLoS Biol. 2019 Jul 3;17(7):e3000365. doi: 10.1371/journal.pbio.3000365. eCollection 2019 Jul.</citation>
    <PMID>31269016</PMID>
  </reference>
  <reference>
    <citation>Zhou Y, Liu Z, Welch JD, Gao X, Wang L, Garbutt T, Keepers B, Ma H, Prins JF, Shen W, Liu J, Qian L. Single-Cell Transcriptomic Analyses of Cell Fate Transitions during Human Cardiac Reprogramming. Cell Stem Cell. 2019 Jul 3;25(1):149-164.e9. doi: 10.1016/j.stem.2019.05.020. Epub 2019 Jun 20.</citation>
    <PMID>31230860</PMID>
  </reference>
  <reference>
    <citation>Peng YR, Shekhar K, Yan W, Herrmann D, Sappington A, Bryman GS, van Zyl T, Do MTH, Regev A, Sanes JR. Molecular Classification and Comparative Taxonomics of Foveal and Peripheral Cells in Primate Retina. Cell. 2019 Feb 21;176(5):1222-1237.e22. doi: 10.1016/j.cell.2019.01.004. Epub 2019 Jan 31.</citation>
    <PMID>30712875</PMID>
  </reference>
  <reference>
    <citation>Filbin MG, Tirosh I, Hovestadt V, Shaw ML, Escalante LE, Mathewson ND, Neftel C, Frank N, Pelton K, Hebert CM, Haberler C, Yizhak K, Gojo J, Egervari K, Mount C, van Galen P, Bonal DM, Nguyen QD, Beck A, Sinai C, Czech T, Dorfer C, Goumnerova L, Lavarino C, Carcaboso AM, Mora J, Mylvaganam R, Luo CC, Peyrl A, Popović M, Azizi A, Batchelor TT, Frosch MP, Martinez-Lage M, Kieran MW, Bandopadhayay P, Beroukhim R, Fritsch G, Getz G, Rozenblatt-Rosen O, Wucherpfennig KW, Louis DN, Monje M, Slavc I, Ligon KL, Golub TR, Regev A, Bernstein BE, Suvà ML. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 Apr 20;360(6386):331-335. doi: 10.1126/science.aao4750.</citation>
    <PMID>29674595</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Fang Wang</investigator_full_name>
    <investigator_title>Chief of department of ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Detachment</mesh_term>
    <mesh_term>Vitreoretinopathy, Proliferative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>To complete the preliminary report of clinical research.evaluation of the clinical protocol.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>2022.12- completing follow-up. Summarizing and analyzing all test data.Comparison of efficacy and summary of adverse reactions.Statistical analysis.Overall outcome evaluation of the clinical protocol.</ipd_time_frame>
    <ipd_access_criteria>All access</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

